Ibogaine Gains Attention as SUD Treatment Option Despite Safety Concerns
Providers are increasingly encountering patients interested in ibogaine, a psychoactive substance being explored for substance use disorder treatment. While ibogaine remains unregulated in the United States and carries cardiac risks, some patients are pursuing treatment domestically or traveling abroad to access it. The article urges providers to understand ibogaine's risks and benefits rather than dismiss it outright, as patient interest continues to grow. No immediate regulatory or policy changes are described.
Medicaid managed care organizations may see members inquiring about or seeking ibogaine treatment for substance use disorder, requiring medical directors to develop clinical guidance and care coordination protocols for this emerging but high-risk intervention.
Behavioral Health
You might also like